Estrella Immunopharma
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5858 Horton St Ste 170, Emeryville, Cali...Phone Number
(510) 318-9098Website
www.estrellabio.comRevenue
<$5 MillionStock Symbol
ESLAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Estrella Immunopharma
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Explore more
Popular SearchesEstrella Immunopharma IncEstrella Biopharma IncEstrella BiopharmaSIC Code 87,873NAICS Code 54,541Ticker NASDAQ: ESLAShow moreEstrella Immunopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Estrella Immunopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Estrella Immunopharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Estrella Immunopharma
Earning: See what the market has to say on Estrella Immunopharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Estrella Immunopharma is spiking on competitors!
Click to see if Estrella Immunopharma had a recent Job posting/layoffs
Estrella Immunopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Estrella Immunopharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Estrella Immunopharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Estrella Immunopharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Estrella Immunopharma
Compare insights from companies similar to Estrella Immunopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Estrella Immunopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Estrella Immunopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Estrella Immunopharma.
Estrella Immunopharma financials insights
Gather financial insights about Estrella Immunopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$3.4M
Estrella Immunopharma Tech Stack
Most Recent Scoops
Funding
Funding
Earnings
Clinical Operations, Operations, Regulations
Earnings
Earnings
Finance, Risk
Earnings
Project
Partnership, Engineering, Product Development, Software, Clinical Operations, Healthcare Technology, Operations
Estrella Immunopharma News & Media
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
Premium-priced $3.35M raise at 50% above market fuels Phase I lymphoma trial. New funding accelerates innovative CD19 T-cell therapy development. Get details.Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that CB Capital Partners has initiated coverage on the Company with a Buy rating and a price target of $14.00. “We appreciate CB Capital’s detailed evaluation of our proprietary ARTEMIS® T-cell platform and the progress we haveEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board (DSMB) has approved the initiation of thEstrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells. In a clinical trial, a c
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Estrella Immunopharma
Sign Up For FreeTo access detailed company insights
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute... Read More
